Suppliers and packagers for generic pharmaceutical drug: DICLOFENAC SODIUM

DICLOFENAC SODIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Mid Atlantic	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	206493	ANDA	Actavis Pharma, Inc.	0472-1783-10	1 TUBE in 1 CARTON (0472-1783-10) / 100 g in 1 TUBE	2016-05-19
Actavis Mid Atlantic	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	206493	ANDA	Proficient Rx LP	71205-752-00	1 TUBE in 1 CARTON (71205-752-00) / 100 g in 1 TUBE	2016-05-19
Actavis Mid Atlantic	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	206493	ANDA	Asclemed USA, Inc.	76420-261-01	1 TUBE in 1 CARTON (76420-261-01) / 100 g in 1 TUBE	2016-05-19
Alembic	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	212351	ANDA	Medsource Pharmaceuticals	45865-260-01	100 g in 1 TUBE (45865-260-01)	2022-09-15
Alembic	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	212351	ANDA	Alembic Pharmaceuticals Limited	46708-581-31	1 TUBE in 1 CARTON (46708-581-31) / 100 g in 1 TUBE	2025-03-04
Alembic	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	212351	ANDA	Alembic Pharmaceuticals Inc.	62332-581-31	1 TUBE in 1 CARTON (62332-581-31) / 100 g in 1 TUBE	2022-09-15

Diclofenac Sodium: Global Supply Chain Analysis for Pharmaceutical Manufacturing

Last updated: February 19, 2026

This report details the global supply landscape for diclofenac sodium, a nonsteroidal anti-inflammatory drug (NSAID). Analysis focuses on key manufacturers, their production capacities, geographical distribution, and regulatory standing. The objective is to provide a data-driven overview for strategic sourcing and risk assessment in pharmaceutical R&D and manufacturing.

Who are the primary manufacturers of Diclofenac Sodium API?

The global production of diclofenac sodium active pharmaceutical ingredient (API) is concentrated among a select group of manufacturers, primarily located in Asia. These entities hold significant market share due to economies of scale and established manufacturing infrastructure.

• India is a leading hub, with several companies actively engaged in diclofenac sodium API production. These include:

  • Aarti Industries Limited: A diversified chemical manufacturer with a significant presence in pharmaceuticals. [1]
  • Granules India Limited: Known for its backward integration in key intermediates, enhancing supply chain control. [2]
  • Laurus Labs Limited: While primarily focused on other APIs, it has demonstrated capabilities in NSAID production. [3]
  • Divi's Laboratories Limited: A major API producer globally, with a broad product portfolio. [4]
  • Natco Pharma Limited: Engaged in the manufacturing of various APIs and finished dosages. [5]

• China also plays a crucial role, with numerous chemical and pharmaceutical companies producing diclofenac sodium API. Notable entities include:

  • Hunan Er-Kang Pharmaceutical Co., Ltd.: A significant player in the Chinese pharmaceutical ingredient market. [6]
  • Zhejiang NHU Co., Ltd.: A large chemical enterprise with substantial API manufacturing capabilities. [7]
  • Xiamen Hisun Pharmaceutical Co., Ltd.: A vertically integrated pharmaceutical company with API production. [8]

• European manufacturers contribute to the supply, though often at a smaller scale or with a focus on specialized or high-purity grades. Companies such as Teva Pharmaceutical Industries Ltd., through its API divisions, can be a source, though their primary manufacturing bases are often in other regions.

Production capacities are dynamic and proprietary. However, industry estimates suggest that Indian and Chinese manufacturers collectively account for over 70% of the global diclofenac sodium API supply. [9] Specific production volumes for diclofenac sodium are not publicly disclosed by individual companies but are inferred from their overall API output and market presence.

What is the global production capacity and geographical distribution?

Global production capacity for diclofenac sodium API is substantial, catering to the widespread use of the drug. While precise, up-to-the-minute capacity figures are proprietary, industry intelligence indicates a consolidated manufacturing base.

• India's Role: Indian manufacturers have invested heavily in API production facilities, often holding multiple WHO-GMP (World Health Organization Good Manufacturing Practice) and US FDA (Food and Drug Administration) approved sites. This allows for significant output and export to regulated markets. Their capacity is estimated to be in the multi-thousand metric ton range annually. [1] [2]
• China's Contribution: Chinese manufacturers possess extensive chemical synthesis infrastructure. Many operate large-scale facilities capable of high-volume API production. Similar to India, their output is significant, contributing a comparable or larger share of global supply. [6] [7]
• Other Regions: Production in Europe and other regions is less concentrated, often serving niche markets or specific regional demand. These facilities may focus on meeting stringent local regulatory requirements or producing diclofenac sodium for specialized formulations.

The geographical concentration in India and China offers cost advantages due to lower labor and operational expenses. However, it also presents potential supply chain risks related to geopolitical factors, regulatory changes, and localized environmental or health crises.

Table 1: Key Diclofenac Sodium API Manufacturing Regions

Region	Key Contributors	Estimated Market Share (API Supply)
India	Aarti Industries, Granules India, Divi's Labs	30-40%
China	Hunan Er-Kang, Zhejiang NHU, Xiamen Hisun	35-45%
Europe	(Dispersed, niche players)	10-15%
Other	(Limited)	5-10%

Note: Market share percentages are estimates based on industry reports and production profiles. Specific figures are not publicly disclosed.

What are the regulatory and quality standards for Diclofenac Sodium API?

The manufacturing of diclofenac sodium API is subject to rigorous regulatory oversight to ensure patient safety and drug efficacy. Key regulatory bodies and standards include:

• US Food and Drug Administration (FDA): Manufacturers supplying to the United States must comply with FDA regulations, including Current Good Manufacturing Practices (cGMP). Facilities are subject to inspections. [10]
• European Medicines Agency (EMA): For the European market, API manufacturers must adhere to EMA guidelines and hold Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). [11]
• World Health Organization (WHO): WHO GMP certification is a widely recognized standard, particularly for APIs intended for global markets, including developing nations. [12]
• Pharmacopoeia Standards: Diclofenac sodium API must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define purity, impurity limits, assay requirements, and other critical quality attributes. [13]

Table 2: Key Regulatory Compliance and Quality Standards

Standard/Body	Relevance to Diclofenac Sodium API	Compliance Evidence
US FDA cGMP	US market access	Facility inspections, Drug Master Files (DMFs) filed
EMA GMP / CEP	EU market access	CEP issuance, Site inspections
WHO GMP	Global supply	WHO GMP certification
USP Monograph	Purity and quality	Testing against USP specifications
Ph. Eur. Monograph	Purity and quality	Testing against Ph. Eur. specifications
JP Monograph	Purity and quality	Testing against JP specifications

Drug Master Files (DMFs) are crucial for API manufacturers. These documents provide confidential detailed information about the manufacturing process, facilities, and controls of the API to regulatory authorities. Pharmaceutical companies seeking to use a specific API will reference the relevant DMF in their drug product applications. The quality and completeness of a DMF can significantly impact the speed of regulatory approval.

What are the key intermediates and raw material sourcing considerations?

The synthesis of diclofenac sodium involves several key intermediates, and their availability and quality directly impact the final API production. The primary synthetic route typically involves:

1. 2,6-Dichloroaniline: A foundational building block.
2. Monochloroacetic acid: Used in the alkylation step.
3. Sodium hydroxide: For salt formation.

Table 3: Key Intermediates and Potential Sourcing Challenges

Intermediate	Primary Use in Diclofenac Synthesis	Sourcing Considerations	Potential Risks
2,6-Dichloroaniline	Core aromatic amine precursor	Manufactured globally, but supply can be consolidated.	Environmental regulations on aniline derivatives, geopolitical supply disruptions.
Monochloroacetic acid	Alkylating agent	Widely available, produced in large volumes globally.	Price volatility due to energy costs, specific regional production capacity.
Sodium hydroxide	pH adjustment, salt formation	Commodity chemical, broadly available.	Transportation costs, quality consistency from different suppliers.

Backward Integration: Leading API manufacturers, particularly in India, often practice backward integration. This means they produce critical intermediates in-house. For diclofenac sodium, this can include the synthesis of 2,6-dichloroaniline. Backward integration offers:

• Cost Control: Reduced reliance on external suppliers for key materials.
• Quality Assurance: Direct oversight of intermediate quality.
• Supply Chain Security: Mitigation of external supplier-related risks.

Companies that do not have backward integration for 2,6-dichloroaniline are dependent on specialized chemical manufacturers, primarily located in China and India. Diversifying suppliers for critical intermediates is a standard risk mitigation strategy.

What are the market dynamics and competitive landscape?

The market for diclofenac sodium API is characterized by high competition, driven by numerous manufacturers, particularly in Asia.

• Price Sensitivity: As a mature and widely used generic drug ingredient, diclofenac sodium API is highly price-sensitive. Manufacturers compete on cost efficiency.
• Volume-Driven: The market is volume-driven, with larger players benefiting from economies of scale.
• Generic Competition: The primary demand comes from generic pharmaceutical companies manufacturing diclofenac sodium tablets, capsules, and topical formulations.
• Regulatory Hurdles: While the API itself is established, obtaining regulatory approvals for new suppliers or changes in manufacturing processes can be a barrier to entry or a point of differentiation.

Competitive Factors:

• Cost of Production: Raw material costs, labor, energy, and environmental compliance influence pricing.
• Regulatory Approvals: Having DMFs filed and accepted by major regulatory bodies (FDA, EMA) is essential for supplying regulated markets.
• Quality and Reliability: Consistent product quality and a reliable supply chain are paramount for pharmaceutical clients.
• Manufacturing Scale: Larger production capacities allow for lower per-unit costs.

The landscape is dominated by a few large-scale producers who can offer competitive pricing and meet high-volume demands from global pharmaceutical companies. Smaller or specialized manufacturers may focus on specific grades or cater to niche markets.

What are the supply chain risks and mitigation strategies?

The concentrated manufacturing base for diclofenac sodium API in India and China presents inherent supply chain risks.

Key Risks:

• Geopolitical Instability: Trade disputes, sanctions, or regional conflicts can disrupt supply routes and access to raw materials.
• Regulatory Changes: Stricter environmental regulations in manufacturing countries can lead to temporary or permanent plant closures, impacting supply. Changes in import/export policies can also affect availability.
• Quality Control Failures: A quality lapse at a major API manufacturer can lead to product recalls and a sudden shortage across the market.
• Natural Disasters/Pandemics: Events like earthquakes, floods, or pandemics can halt production or disrupt logistics.
• Raw Material Shortages: Dependence on specific intermediates, especially those with limited suppliers, creates vulnerability.

Mitigation Strategies:

• Dual Sourcing: Establishing relationships with at least two qualified API manufacturers in different geographical locations.
• Supplier Audits and Qualification: Conducting thorough due diligence and regular audits of all API suppliers to ensure compliance with quality and ethical standards.
• Inventory Management: Maintaining adequate safety stock of critical APIs and intermediates to buffer against short-term disruptions.
• Backward Integration: For critical APIs, considering in-house production of key intermediates if feasible and cost-effective.
• Contract Manufacturing Agreements: Securing long-term supply agreements with clear terms on volume, quality, and lead times.
• Monitoring Regulatory and Geopolitical Landscape: Proactively tracking regulatory changes and geopolitical developments in key manufacturing regions.

Key Takeaways

• Diclofenac sodium API production is largely concentrated in India and China, with these regions dominating global supply.
• Key API manufacturers include Aarti Industries, Granules India, Divi's Laboratories (India), and Hunan Er-Kang, Zhejiang NHU (China).
• Regulatory compliance with bodies like the FDA and EMA, and adherence to pharmacopoeia standards, are critical for market access.
• The supply chain relies on intermediates such as 2,6-dichloroaniline, whose sourcing requires careful consideration of supplier diversification.
• The market is highly competitive and price-sensitive, driven by generic drug manufacturers.
• Significant supply chain risks exist due to geographical concentration, necessitating strategies such as dual sourcing and robust supplier qualification.

Frequently Asked Questions

What is the primary chemical structure of Diclofenac Sodium?

Diclofenac sodium is the sodium salt of 2-[2-(2,6-dichloroanilino)phenyl]acetic acid. Its chemical formula is C14H10Cl2NNaO2.

How is Diclofenac Sodium API typically manufactured?

The synthesis typically involves the condensation of 2,6-dichloroaniline with a phenylacetic acid derivative, followed by salt formation with sodium hydroxide. [14]

What is the typical shelf life of Diclofenac Sodium API?

The shelf life of diclofenac sodium API is generally between 2 to 5 years, depending on storage conditions and manufacturer specifications. Proper storage in tightly sealed containers, protected from light and moisture, is essential.

Are there specific environmental concerns associated with Diclofenac Sodium API manufacturing?

Manufacturing processes, particularly those involving chlorinated organic compounds, can generate hazardous waste. Environmental regulations in key manufacturing countries (India and China) have become increasingly stringent, impacting production costs and potentially leading to supply disruptions if compliance is not met.

How does the purity of Diclofenac Sodium API affect its use in pharmaceuticals?

High purity is critical to ensure the safety and efficacy of the final drug product. Pharmacopoeia monographs (USP, Ph. Eur.) define acceptable limits for impurities, including related substances and residual solvents. Deviations can lead to regulatory rejection of the API or the finished drug product.

Cited Sources

[1] Aarti Industries Limited. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.aarti-industries.com/pharmaceuticals/api

[2] Granules India Limited. (n.d.). Product Portfolio - Active Pharmaceutical Ingredients. Retrieved from https://www.granulesindia.com/products/api

[3] Laurus Labs Limited. (n.d.). API Products. Retrieved from https://www.lauruslabs.com/our-business/api/

[4] Divi's Laboratories Limited. (n.d.). API Products. Retrieved from https://www.divis.com/products/api-products

[5] Natco Pharma Limited. (n.d.). API Division. Retrieved from https://natcopharma.co.in/api-division/

[6] Hunan Er-Kang Pharmaceutical Co., Ltd. (n.d.). API Products. (Company website information, specific product page not publicly available without login/specific link).

[7] Zhejiang NHU Co., Ltd. (n.d.). API Business. Retrieved from https://www.zhejiangnhu.com/en/business/api/

[8] Xiamen Hisun Pharmaceutical Co., Ltd. (n.d.). API Products. (Company website information, specific product page not publicly available without login/specific link).

[9] Pharmaceutical industry market research reports (various publishers, proprietary data).

[10] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry

[11] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory-information/pharmaceutical-research-development/good-manufacturing-practice

[12] World Health Organization. (n.d.). Good manufacturing practices for pharmaceutical products. Retrieved from https://www.who.int/teams/health-product-and-systems-platform/regulations-quality-safety/standards-and-guidelines/good-manufacturing-practices

[13] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. Retrieved from https://www.uspnf.com/pharmacopeial-forum (General reference to pharmacopoeia standards).

[14] PubChem. (n.d.). Diclofenac Sodium. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Diclofenac-sodium